Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.

Abstract StaphVAX ® , an unadjuvanted, bivalent vaccine composed of Staphylococcus aureus ( S. aureus ) capsular polysaccharides (CPS) types 5 and 8 bound to the mutant non-toxic recombinant Pseudomonas aeruginosa exotoxin A (rEPA) conferred ∼60% protection for 10 months against bacteremia caused by this pathogen in hemodialysis patients. A protective level of 80 μg/ml was estimated based upon geometric mean (GM) antibody levels at the end of the efficacy period. To extend the duration of protection conferred by StaphVAX ® in hemodialysis patients, recipients of the vaccine were reinjected in a randomized double-blinded, placebo-controlled study. Vaccinees received StaphVAX ® and a saline placebo injection 14 days apart according to the randomization schedule. The booster dose of StaphVAX ® was administered an average of 958 days (753–1167 days) after the first injection. There were no serious adverse reactions. Antibody levels at day 14, 28, 92, and 182 post-injection were measured by ELISA. Maximal levels of IgG anti-CPS were observed at the 28-day interval. For type 5, GM antibody levels increased from 73 μg/ml at day 0 to 162 μg/ml ( P P r = 0.93). Moreover, the decline of anti-CPS antibody levels at six months was significantly less rapid than that observed from the first immunization ( P S. aureus bacteremia.